Inhibrx Biosciences: planeja submeter BLA para ozekibart no 2T 2026

Inhibrx Biosciences anunciou planos de submeter uma biologics license application (BLA) à U.S. Food and Drug Administration para ozekibart no segundo trimestre de 2026. Isso segue resultados positivos de topline do ensaio registracional de ozekibart em condrossarcoma, onde atingiu seu endpoint primário.

Fatos principais

Arquivado: 13 de nov. de 2025, 23:00
Evento: Pedido submetido
Direção: Positivo
Empresa: INBXInhibrx
Ativo: ozekibart
Fonte: SEC 8-K
Confiança: Com fonte

Trecho da fonte

EX-99.1 2 exhibit99109302025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Third Quarter 2025 Financial Results San Diego, CA, November 14, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the “101 Transaction”) by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Recent Corporate Highlights On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing s

SEC 8-K